Physician profile
Mitchell Supler
NPI 1114990553
$49,075.89
in general payments reported to CMS, 2019-2025
33 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,040 · 2021: $8,788 · 2022: $19K · 2023: $740 · 2024: $3,475 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403 · Consulting Fee: $2,000 · Travel and Lodging: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,402.80 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $1,755.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29,158.31 | 2019-2025 | Infinion 16, General - Pain Management, General - Therapies |
| Spinesmith Holdings, LLC | $8,977.92 | 2019-2021 | |
| Osteocentric Technologies, INC. | $4,626.09 | 2023-2025 | Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St |
| Alevio, LLC | $2,167.76 | 2019-2022 | |
| Globus Medical, INC. | $887.15 | 2024 | Excelsiusgps Robotic Navigation System |
| Intrinsic Therapeutics | $356.31 | 2022 | |
| Spineology INC. | $351.40 | 2021-2022 | |
| Orthofix Medical, INC. | $285.89 | 2019-2024 | Spinal-Stim, Spinal-Stim |
| Nevro Corp. | $224.83 | 2019-2024 | Senza |
| Arthrex, INC. | $204.95 | 2024 | |
| Providence Medical Technology, INC. | $199.17 | 2019 | |
| Zavation Medical Products, LLC | $154.67 | 2023 | |
| Spinal Elements, INC. | $145.86 | 2023-2024 | |
| Abbott Laboratories | $132.83 | 2024-2025 | Eterna, Proclaim |
| Amplify Surgical, INC. | $121.53 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $121.16 | 2024-2025 | Pico 14 |
| Surgalign Spine Technologies, INC. | $119.68 | 2019 | |
| Kuros Biosciences USA, INC | $116.40 | 2023 | |
| Vertiflex, INC. | $113.08 | 2019 | |
| Si-Bone, INC. | $109.61 | 2019-2022 | |
| Centinel Spine, LLC | $69.42 | 2019 | |
| Theragen, INC. | $66.53 | 2022-2025 | Actastim-S |
| Pacira Pharmaceuticals Incorporated | $63.97 | 2024-2025 | Exparel |
| Curonix LLC | $47.97 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Zimvie INC. | $39.30 | 2023 | |
| Ebi, LLC | $38.78 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Reel Surgical, INC. | $36.05 | 2024 | |
| Averitas Pharma INC. | $31.79 | 2024 | Qutenza |
| Stryker Corporation | $25.77 | 2021 | |
| Abbvie INC. | $25.55 | 2025 | |
| Medtronic, INC. | $22.77 | 2023 | Kyphon Express II Kyphopak Tray |
| Sanara Medtech INC. | $18.60 | 2025 | Celleraterx |
| Kowa Pharmaceuticals America, INC. | $14.79 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Supler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.